Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 15INDUSTRY 9NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1Neuroblastoma 1

Interventions

Cisplatin 24Radiotherapy 18Carboplatin 18Paclitaxel 17Vincristine 15Cyclophosphamide 14Etoposide 13Filgrastim 12Doxorubicin 12Gemcitabine 11Temozolomide 10Cytarabine 9Topotecan 8Docetaxel 8Methotrexate 7Irinotecan 7Granulocyte Colony-Stimulating Factor 7Dexamethasone 7Taxes 6Radiation 6Peripheral Blood Stem Cell Transplantation 6Radiotherapy, Conformal 5Oxaliplatin 5Melphalan 5Fenretinide 5Chemotherapy, Adjuvant 5Capecitabine 5etoposide phosphate 4Trastuzumab 4Platinum 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NETWORK × irinotecan sucrosofate × Clear all
NCT02013336 2022-03-31

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

South Plains Oncology Consortium

Phase 1 Unknown
30 enrolled
CNSSarcoma

Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡